List of Excipients in Branded Drug GADOTERATE MEGLUMINE

Generic Drugs Containing GADOTERATE MEGLUMINE

Company	Ingredient	NDC	Excipient
Fresenius Kabi USA LLC	gadoterate meglumine	65219-080	TETRAXETAN
Fresenius Kabi USA LLC	gadoterate meglumine	65219-080	WATER
Fresenius Kabi USA LLC	gadoterate meglumine	65219-088	TETRAXETAN
Fresenius Kabi USA LLC	gadoterate meglumine	65219-088	WATER
Slate Run Pharmaceuticals LLC	gadoterate meglumine	70436-123	TETRAXETAN
Slate Run Pharmaceuticals LLC	gadoterate meglumine	70436-123	WATER

What are the Most Frequently-Used Excipients in GADOTERATE MEGLUMINE?

# Of NDCs	Excipient
3	TETRAXETAN
3	WATER

Last updated: August 11, 2026

Gadoterate meglumine has limited conventional excipient opportunities because the marketed injection is a sterile, aqueous, preservative-free formulation with a short ingredient list. The strongest commercial opportunities are in device-enabled delivery, ready-to-use presentations, container closure systems, manufacturing efficiency, and differentiated administration workflows. New excipients are more likely to increase regulatory and compatibility risk than create meaningful product value.

Gadoterate Meglumine Excipient Strategy and Commercial Opportunities

Gadoterate meglumine is a macrocyclic, ionic gadolinium-based contrast agent used for magnetic resonance imaging. The reference product, Dotarem, is supplied as an intravenous injection containing gadoterate meglumine at 279.32 mg/mL, equivalent to 0.5 mmol/mL of gadolinium, in water for injection.[1]

The formulation’s commercial logic is straightforward:

• Preserve chemical and physical stability.
• Minimize particulate, microbial, and extractables risk.
• Maintain rapid intravenous administration.
• Support high-throughput radiology workflows.
• Avoid unnecessary excipients that complicate regulatory review.
• Differentiate through packaging, dosing accuracy, and supply reliability.

What excipients are used in gadoterate meglumine injection?

The approved Dotarem formulation contains gadoterate meglumine and water for injection. The formulation does not rely on a conventional preservative, surfactant, antioxidant, or complex buffering system.[1]

Formulation element	Role	Commercial significance
Gadoterate meglumine	Active gadolinium complex and meglumine salt	Provides MRI contrast and controls ionic formulation characteristics
Water for injection	Vehicle	Supports parenteral administration
Container closure system	Maintains sterility and product integrity	Creates opportunities in syringe, vial, stopper, and packaging design
Manufacturing controls	Controls sterility, osmolality, concentration, and particulates	Supports generic approval and supply differentiation

Meglumine should not be treated as a conventional inactive excipient in commercial analysis. It is the counterion component of the gadoterate meglumine drug substance. Adding separate meglumine, buffer, or pH-adjusting agents would require a clear technical rationale.

Why is a minimal-excipient strategy appropriate for gadoterate meglumine?

A minimal-excipient formulation reduces several risks relevant to injectable contrast agents.

First, fewer ingredients reduce the number of potential incompatibility pathways. Gadoterate meglumine products must remain stable during storage, transport, preparation, and administration. The formulation also must meet stringent requirements for sterility, particulate matter, endotoxins, visible appearance, and container closure integrity.

Second, a low-excipient formulation reduces the risk of introducing new safety concerns in a product administered intravenously to large patient populations. Excipients that are acceptable in oral or topical products may require additional justification in a high-volume injectable imaging product.

Third, a simple composition can simplify generic development. An abbreviated new drug application may rely on pharmaceutical equivalence and bioequivalence or other product-specific requirements established by FDA. A materially different excipient system can create additional questions regarding stability, impurity formation, osmolality, viscosity, injection performance, and safety.

The principal limitation is that a formulation with no differentiated excipient platform offers little traditional composition-of-matter protection. Commercial value must therefore come from product presentation, manufacturing performance, supply economics, or workflow integration.

What formulation characteristics must a gadoterate meglumine product preserve?

A competing product should preserve the key attributes of the reference injection:

• Gadoterate concentration of approximately 279.32 mg/mL.
• Gadolinium concentration of 0.5 mmol/mL.
• Suitable pH and osmolality for intravenous use.
• Chemical stability of the gadoterate complex.
• Low particulate burden.
• Sterility through the labeled shelf life.
• Compatibility with automated injectors and transfer devices.
• Consistent fill volume and dose accuracy.
• Acceptable container closure integrity.

The most defensible formulation work is likely to focus on critical quality attributes rather than adding excipients. These attributes include assay, free gadolinium, degradation products, pH, osmolality, viscosity, sterility, endotoxin levels, visible and subvisible particles, and extractables and leachables.

What excipient technologies could create commercial differentiation?

Buffer-free or low-buffer systems

The reference product’s simple formulation creates an incentive to preserve a low-buffer or buffer-free approach. A buffer may improve pH control during development, but it can also increase ionic content, compatibility questions, and regulatory burden.

A buffer could be commercially useful if it improves long-term stability, reduces pH drift, or supports a specific container closure system. The opportunity is narrow because any benefit must outweigh the cost of introducing another parenteral ingredient.

Surfactants and solubilizers

Surfactants are unlikely to be necessary for a fully aqueous gadoterate meglumine injection. They may become relevant only if a developer pursues a concentrated product, a novel delivery device, or a reformulation with a different solvent system.

The risk profile is unfavorable for routine use. Surfactants can affect subvisible particles, protein or polymer interactions, foaming, syringeability, and extractables. They also create additional toxicological and compatibility questions.

Tonicity modifiers

A separate tonicity modifier could be considered if a new formulation changes concentration, administration volume, or delivery route. For the standard 0.5 mmol/mL injection, the formulation already has defined ionic and osmolality characteristics. Adding sodium chloride or another tonicity agent could alter viscosity, osmolality, and injection performance without producing a clear clinical benefit.

Antioxidants and chelating agents

Antioxidants are generally unattractive unless a defined oxidative degradation pathway has been demonstrated. Additional chelating agents may interfere with the intended gadolinium complex or create analytical and safety concerns. The core product already depends on a stable macrocyclic chelate, so additive chelation requires particularly strong justification.

Novel excipients

Novel excipients have limited near-term value for a conventional gadoterate meglumine injection. They may be relevant to a nonstandard delivery platform, but the regulatory burden is likely to exceed the commercial benefit for routine MRI contrast use.

What formulations are protected by gadoterate meglumine patents?

The principal commercial barrier for gadoterate meglumine is unlikely to be a broad excipient patent. The active product has a relatively simple aqueous formulation, and generic competition can focus on pharmaceutical equivalence, manufacturing controls, and presentation.

Potentially protectable subject matter includes:

• Specific concentration or pH ranges.
• Stability profiles tied to a defined container closure.
• Low-particulate manufacturing processes.
• Prefilled syringe configurations.
• Automated injector compatibility.
• Multi-dose or unit-dose packaging systems.
• Methods that reduce preparation time or product waste.
• Packaging that limits light, oxygen, or moisture exposure.
• Manufacturing processes controlling free gadolinium or degradation products.

A formulation patent must connect the claimed excipient or process feature to a measurable technical advantage. A patent directed only to the presence of a routine parenteral excipient would face greater validity and obviousness risk.

What is the FDA regulatory status of gadoterate meglumine?

FDA approved Dotarem, gadoterate meglumine injection, under NDA 203696 in 2013 for intravenous use in adults and pediatric patients aged 2 years and older for MRI of the central nervous system.[2] The product is a prescription diagnostic drug and is regulated as a gadolinium-based contrast agent.

The FDA label identifies warnings associated with gadolinium-based contrast agents, including nephrogenic systemic fibrosis risk in susceptible patients and retention of gadolinium in the body.[1] These safety considerations affect the commercial value of reformulation. An excipient change that does not improve diagnostic performance, administration, or safety is unlikely to support premium pricing.

FDA development implications

A developer pursuing a new gadoterate meglumine product must manage:

1. Drug substance characterization and complexation control.
2. Sterile manufacturing validation.
3. Container closure integrity.
4. Compatibility with administration systems.
5. Comparative physicochemical testing.
6. Stability and degradation studies.
7. Particulate and extractables testing.
8. Product-specific FDA requirements for an abbreviated application.

The simplest path is usually a formulation close to the reference product. A differentiated formulation may be commercially stronger but carries higher development and regulatory risk.

What is the Orange Book status of gadoterate meglumine?

The FDA Orange Book is the source of record for patents and regulatory exclusivities associated with approved drug products.[3] For gadoterate meglumine, the practical market assessment should distinguish three categories:

Protection category	Relevance to gadoterate meglumine
Active ingredient patent	Limited commercial relevance for a mature contrast agent
Formulation patent	Potentially relevant if tied to a specific stability or presentation advantage
Method-of-use patent	Potentially relevant for a narrowly claimed imaging indication or patient population
Regulatory exclusivity	Primarily relevant near initial approval; mature products generally face reduced exclusivity barriers
Device or packaging patent	Potentially valuable for prefilled syringes, injectors, or closed-system administration

An Orange Book-listed patent would affect an ANDA applicant’s certification strategy and potential Paragraph IV litigation. A patent not listed in the Orange Book could still create risk through separate patent litigation, although it would not necessarily produce the same statutory stay mechanism associated with a listed patent.

When does gadoterate meglumine lose exclusivity?

Gadoterate meglumine is a mature FDA-approved product. The original approval dates from 2013, and the principal commercial opportunity now relates to generic entry and product differentiation rather than preservation of initial regulatory exclusivity.[2]

A generic applicant may pursue an ANDA when the relevant regulatory and patent barriers permit. The timing depends on:

• Orange Book-listed patents.
• Any unexpired formulation or process patents.
• Paragraph IV certifications.
• Litigation and possible 30-month stays.
• FDA approval readiness.
• Manufacturing inspection status.
• Commercial launch strategy.

No single expiry date determines the entire market. A product can lose primary exclusivity while still facing narrower patents involving packaging, preparation, manufacturing, or use.

Which companies are challenging or competing with Dotarem?

The competitive market includes:

• Generic gadoterate meglumine injection manufacturers.
• Guerbet, the originator associated with Dotarem.
• Other macrocyclic gadolinium products, including gadobutrol and gadoteridol.
• Linear gadolinium-based contrast agents used in selected clinical settings.
• Hospital purchasing groups and radiology distributors.
• Contract manufacturers with sterile injectable capacity.

Competition is based on more than active ingredient price. Hospitals and imaging centers evaluate supply continuity, injector compatibility, vial and syringe formats, waste, contract terms, product availability, and radiology workflow.

How does gadoterate meglumine compare with competing gadolinium agents?

Product	Chelate class	General formulation opportunity	Commercial positioning
Gadoterate meglumine	Macrocyclic ionic	Minimal-excipient aqueous injection; device and packaging differentiation	Broad MRI use with emphasis on macrocyclic stability
Gadobutrol	Macrocyclic nonionic	Concentration, delivery volume, and injector compatibility	Higher-concentration product with workflow implications
Gadoteridol	Macrocyclic nonionic	Low-excipient injectable and presentation differentiation	Competes in macrocyclic GBCA segment
Gadopentetate dimeglumine	Linear ionic	Mature generic and cost-focused strategies	Older product with different safety and market dynamics
Gadobenate dimeglumine	Linear ionic	Indication and formulation-specific strategies	Differentiation may depend on approved clinical uses

Macrocyclic agents generally compete on perceived stability, clinical familiarity, availability, and price. Excipient innovation alone is unlikely to displace an established product. A more credible strategy combines a simple formulation with a better delivery format.

What are the strongest commercial opportunities for gadoterate meglumine?

Ready-to-use prefilled syringes

Prefilled syringes can reduce manual transfer steps, preparation time, and dosing errors. They may support premium pricing if they reduce waste or improve radiology department throughput.

Key development issues include:

• Syringe material compatibility.
• Silicone oil and particle control.
• Plunger movement and break-loose force.
• Extractables and leachables.
• Needle-free or closed-system connectivity.
• Automated injector compatibility.
• Dose labeling and traceability.

Unit-dose packaging

Unit-dose presentations can support outpatient imaging, emergency imaging, and high-volume radiology departments. Packaging should align with common patient dose ranges while avoiding excessive residual volume.

Low-waste formats

A low-waste vial or syringe may have value where administered doses vary substantially by patient weight. The opportunity is strongest when the presentation reduces discarded contrast without increasing inventory complexity.

Automated injector integration

Closed-system transfer, injector-ready syringes, barcode integration, and dose documentation can create more defensible commercial differentiation than a new excipient.

Contract manufacturing and private-label supply

The mature product category may support partnerships with hospital systems, distributors, and diagnostic imaging suppliers. Sterile injectable capacity, reliable supply, and flexible packaging can be more valuable than a proprietary excipient platform.

What manufacturing and intellectual-property barriers affect market entry?

The principal barriers are technical and operational:

• Sterile fill-finish capacity.
• Control of gadolinium complex purity.
• Prevention of particulate contamination.
• Consistent pH and osmolality.
• Container closure integrity.
• Compatibility with plastic syringes and elastomeric components.
• Stable supply of pharmaceutical-grade drug substance.
• Validation of automated injector performance.
• Compliance with current good manufacturing practice requirements.

Process patents may be stronger than conventional excipient patents when they claim a reproducible method for controlling impurities, improving shelf life, or reducing particulate formation. A process claim supported by comparative stability data has greater commercial value than a broad claim to a routine formulation additive.

What generic launch scenarios exist for gadoterate meglumine?

Price-led generic launch

A manufacturer may enter with a formulation close to the reference product and compete through low acquisition cost. This strategy requires efficient sterile manufacturing and dependable supply.

Presentation-led launch

A prefilled syringe, injector-compatible package, or lower-waste format may support a price premium. The product must demonstrate measurable workflow or utilization benefits.

Dual-channel launch

A supplier may offer both vials for price-sensitive hospitals and prefilled syringes for outpatient imaging centers. This approach increases manufacturing complexity but expands account coverage.

Supply-security launch

Hospitals may accept a modest premium for a second source when contrast shortages or supply disruptions create operational risk. Regulatory approval and validated backup capacity are central to this strategy.

How strong is the patent estate for gadoterate meglumine?

The patent estate is likely strongest around implementation rather than the basic aqueous formulation. Commercially relevant claim categories include packaging, injector systems, sterile manufacturing, impurity control, and specific stability profiles.

Patent category	Relative opportunity	Main vulnerability
Basic gadoterate meglumine composition	Low for new entrants	Prior art and mature product history
Routine aqueous formulation	Low	Obviousness and lack of unexpected results
Narrow pH or concentration range	Low to moderate	Limited clinical or technical differentiation
Stability-enhancing formulation	Moderate	Must show unexpected stability benefit
Prefilled syringe system	Moderate to high	Design-around risk
Automated injector integration	Moderate to high	Device and combination-product complexity
Manufacturing impurity control	Moderate	Enablement and reproducibility requirements
Low-waste packaging	Moderate	Functional claiming and obviousness risk

What licensing deals could support gadoterate meglumine commercialization?

Potential licensing structures include:

• Drug substance supply agreements.
• Regional commercialization licenses.
• Co-development of prefilled syringe presentations.
• Contract fill-finish partnerships.
• Injector compatibility licenses.
• Hospital or distributor private-label arrangements.
• Technology licenses covering container closure or automated administration.

The most attractive deal structure would link a formulation or device asset to a measurable operational outcome, such as lower residual waste, reduced preparation time, or improved injector utilization. A license based only on a new excipient is less likely to command strong economics.

What is the revenue exposure and market opportunity?

Revenue exposure depends on product share, imaging volume, pricing, and the pace of generic substitution. Gadoterate meglumine is used in a recurring diagnostic workflow, which supports stable demand, but hospital and group-purchasing pressure can compress margins.

The highest-value commercial segments are likely to be:

• Large hospital radiology departments.
• Outpatient imaging networks.
• Pediatric MRI centers.
• Emergency imaging facilities.
• Sites with automated injector infrastructure.
• Markets with recurring contrast shortages.
• Regions where local sterile manufacturing is strategically important.

A differentiated product can target gross-margin preservation rather than broad market expansion. The commercial case is strongest when packaging reduces labor, preparation risk, or unused product.

Key Takeaways

• Gadoterate meglumine has a simple aqueous formulation centered on the active gadolinium complex and water for injection.
• Conventional excipient innovation has limited value and may add regulatory and compatibility risk.
• The strongest opportunities are prefilled syringes, injector-ready formats, low-waste packaging, and supply reliability.
• Manufacturing process patents may offer more defensible protection than routine formulation patents.
• Generic competition is likely to be driven by cost, availability, and presentation.
• FDA approval dates from 2013, placing the product in a mature commercial phase.
• Orange Book and non-Orange Book patent review remain important for Paragraph IV and launch analysis.
• A premium product must demonstrate measurable workflow, safety, stability, or waste-reduction benefits.

FAQs

Can gadoterate meglumine be reformulated with sodium chloride?

It can be evaluated technically, but a separate tonicity modifier is not automatically commercially justified. The developer would need to demonstrate an advantage in osmolality, stability, administration, or packaging.

Is gadoterate meglumine suitable for a preservative-containing multidose vial?

A multidose presentation would require a strong microbiological and safety rationale. A preservative-free single-dose format is generally more consistent with intravenous contrast-agent use and hospital workflow.

Can a prefilled gadoterate meglumine syringe receive patent protection?

Potentially. Protection may be available for a defined combination of formulation, syringe materials, closure components, injector interface, dose configuration, or manufacturing process. Patent strength depends on novelty, nonobviousness, enablement, and measurable performance benefits.

Does gadoterate meglumine require a novel excipient for pediatric MRI use?

No. Pediatric use does not inherently require a novel excipient. Dose flexibility, accurate small-volume delivery, low residual volume, and suitable packaging are more commercially relevant.

Could a gadoterate meglumine product be developed as an oral or intramuscular contrast agent?

The established product is an intravenous MRI contrast agent. A different route would require a new clinical, formulation, pharmacology, safety, and regulatory development program rather than a conventional generic reformulation.

References

1. U.S. Food and Drug Administration. (2024). Dotarem (gadoterate meglumine) injection prescribing information. Guerbet LLC.

2. U.S. Food and Drug Administration. (2013). FDA approves Dotarem for use with magnetic resonance imaging. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. American College of Radiology. (2024). ACR manual on contrast media. American College of Radiology.